Enanta Pharmaceuticals | ENTA - Trade Creditors


Enanta Pharmaceuticals reported $1.88M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Amgen USD 19.52B 1.37B Mar/2026
Anika Therapeutics USD 6.34M 298K Mar/2026
Arrowhead Research USD 30.75M 2.19M Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Heron Therapeutics USD 8.97M 24K Mar/2026
Immunic USD 11.01M 873K Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
Insmed USD 73.38M 6.53M Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
J&J USD 9.22B 1.24B Jun/2026
Karyopharm Therapeutics USD 4M 1.39M Dec/2025
Ligand Pharmaceuticals USD 37.11M 33.87M Mar/2026
Merck USD 3.86B 541M Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Novavax USD 16.1M 8.48M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026